CoChat

Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1 H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor

Open access
McDaniel, Keith F., Wang, Le, Soltwedel, Todd, Fidanze, Steven D., Hasvold, Lisa A., Liu, Dachun, Mantei, Robert A., Pratt, John K., Sheppard, George S., Bui, Mai H., Faivre, Emily J., Huang, Xiaoli, Li, Leiming, Lin, Xiaoyu, Wang, Rongqi, Warder, Scott E., Wilcox, Denise, Albert, Daniel H., Magoc, Terrance J., Rajaraman, Ganesh, Park, Chang H., Hutchins, Charles W., Shen, Jianwei J., Edalji, Rohinton P., Sun, Chaohong C., Martin, Ruth, Gao, Wenqing, Wong, Shekman, Fang, Guowei, Elmore, Steven W., Shen, Yu, Kati, Warren M. · 2017 · Journal of Medicinal Chemistry
Cited by 135

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

The development of bromodomain and extraterminal domain (BET) bromodomain inhibitors and their examination in clinical studies, particularly in oncology settings, has garnered substantial recent interest. An effort to generate novel BET bromodomain inhibitors with excellent potency and drug metabolism and pharmacokinetics (DMPK) properties was initiated based upon elaboration of a simple pyridone core. Efforts to develop a bidentate interaction with a critical asparagine residue resulted in the incorporation of a pyrrolopyridone core, which improved potency by 9-19-fold. Additional structure-activity relationship (SAR) efforts aimed both at increasing potency and improving pharmacokinetic properties led to the discovery of the clinical candidate 63 (ABBV-075/mivebresib), which demonstrates excellent potency in biochemical and cellular assays, advantageous exposures and half-life both in animal models and in humans, and in vivo efficacy in mouse models of cancer progression and inflammation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.7b00746

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 135

Metadata

Authors
McDaniel, K. F., Wang, L., Soltwedel, T., Fidanze, S. D., Hasvold, L. A., Liu, D., Mantei, R. A., Pratt, J. K., Sheppard, G. S., Bui, M. H., Faivre, E. J., Huang, X., Li, L., Lin, X., Wang, R., Warder, S. E., Wilcox, D., Albert, D. H., Magoc, T. J., Rajaraman, G., Park, C. H., Hutchins, C. W., Shen, J. J., Edalji, R. P., Sun, C. C., Martin, R., Gao, W., Wong, S., Fang, G., Elmore, S. W., Shen, Y., & Kati, W. M.
Venue
Journal of Medicinal Chemistry
Published
2017-10-12
Volume
60
Issue
20
Pages
8369-8384
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2760757128
Cited by
135
References
4
FWCI
4.17
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1 H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor. https://app.cochat.ai/papers/10.1021/acs.jmedchem.7b00746
The paper
McDaniel, K. F., Wang, L., Soltwedel, T., Fidanze, S. D., Hasvold, L. A., Liu, D., Mantei, R. A., Pratt, J. K., Sheppard, G. S., Bui, M. H., Faivre, E. J., Huang, X., Li, L., Lin, X., Wang, R., Warder, S. E., Wilcox, D., Albert, D. H., Magoc, T. J., . . . Kati, W. M. (2017). Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1 H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.7b00746

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.